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Editorial on the Research Topic
The Translational and Therapeutic Potential of the Tumor Microenvironment in Oral Cancer
It is now recognized that the tumor microenvironment (TME) can influence all the
essential hallmarks of cancer, contributing to growth, progression and treatment response of
tumors. The TME is composed of many cellular components including a vast repertoire of
immune/inflammatory cells, blood and lymphatic vessels, peripheral nervous structures, fibroblasts
and an array of non-cellular components such as extracellular matrix proteins, cytokines and
growth factors. As the TME is a crucial part of the tumor, its components have become one of the
key targets for tumor treatment. Although many strategies to target the TME have been developed,
the results so far are disappointing, with limited impact observed on tumor burden or overall
survival. This special collection encompassed 7 reviews and 2 original articles dedicated to the
translational and therapeutic potential of the TME in oral cancer, highlighting opportunities and
the need to concentrate efforts to overcome the barriers to develop new and efficient TME-targeted
therapeutic strategies.
Several of the studies discuss emerging findings related to the tumor-infiltrating
immune/inflammatory cells. It is becoming clear that a cause-effect relationship exists
between inflammation and cancer, and Elebyary et al. performed an extensive review in the
putative connection between oral carcinogenesis and the chronic inflammation associated with
periodontitis. The authors provided evidence that the inflammatory milieu in periodontitis is ideal
for cancer cell seeding, migration, proliferation and immune escape. Moreover, the authors showed
evidence that dental biofilm (bacterial)-derived substances may contribute to the induction of
permanent genomic alterations. Niklander extensively reviewed the literature to characterize the
major TME-associated inflammatory cells and mediators that may contribute to proliferation
and spread of oral cancer cells. This study also highlighted the rationale for detection of salivary
inflammatory factors as biomarkers for the diagnosis of oral squamous cell carcinoma (OSCC).
Evasion of immune surveillance and induction of an immunosuppressive TME are common
features of the head and neck squamous cell carcinomas (HNSCC), and one of the main
immune escape mechanisms includes the overexpression of the programmed death ligand-1
(PD-L1) in the surface of the tumor cells. The article by Wondergem et al. reviewed the
currently approved immune checkpoint inhibitors (drugs that block immune checkpoint proteins
such as PD-L1) in HNSCC, including nivolumab and pembrolizumab (anti-PD-1 antibodies),
and highlighted the potential benefits of modulating STAT3 and in PI3K/AKT/mTOR and
Wnt pathways to boost the response to these inhibitors and prevent drug resistance. In
this context, Dobriyan et al. reported the differences in the immune/inflammatory cells
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and cancer-associated fibroblasts (CAFs) between patients with
OSCC treated with neoadjuvant pembrolizumab that displayed
complete or incomplete remission. In the patients with complete
remission, the tumor was replaced by a granulomatous type of
inflammation, enriched with T lymphocytes, with approximately
equal amounts of CD4+ and CD8+ cells, numerous CD68+
and CD163+ macrophages and absence of CAFs. The tumors
with incomplete remission showed a moderate inflammatory
response, with a variable CD4+/CD8+ ratio, and the presence of
CAFs. These encouraging results warrant further investigation in
large cohorts.
Hypoxia is an important feature of the TME, and the
review by Chaudhary et al. explored its effects on the
crosstalk between OSCC cells and immune cells. The authors
reported that in the hypoxic microenvironment, OSCC cells
and other TME components secrete immunosuppressive onco-
metabolites that regulate immune escape, via disturbing redox
balance, mitochondrial function and ATP production through
aerobic glycolysis.
The connection between inflammation and oral
carcinogenesis was also reviewed in Niklander et al. by
exploring the roles of interleukin 1 (IL-1) signaling, which
has been shown to be activated in several types of tumors, in
HNSCC. After reviewing important roles of the main IL-1 family
members in the growth, differentiation and aging of normal
oral keratinocytes, the authors showed that the dysregulated
expression of IL-1 and IL-1R are associated with the acquisition
of malignant phenotypes and reduced survival in HNSCC.
The authors also provided evidence of the potential of IL-1
family members as diagnostic biomarkers and as attractive
therapeutic targets for HNSCC. The participation of the
IL-1/IL-1R axis in oropharyngeal squamous cell carcinomas
(OPSCC) was investigated in Al-Sahaf et al.. Initially the authors
demonstrated that HPV-negative OPSCC contained significantly
more neutrophils than HPV-positive tumors. Applying a 3D
cell culture model with HPV-negative or HPV-positive OPSCC
cells in the presence of anakinra, an IL-1R inhibitor, the
authors showed that both chemokine secretion and neutrophil
recruitment are dependent on IL-1β/IL-1R paracrine signaling.
These features make IL-1/IL-1R axis promising biomarkers and
therapeutic targets for HNSCC.
The role of CAFs in OSCC is extensively reviewed
in Bienkowska et al.. Besides summarizing our current
understanding of CAF subtypes and function in controlling
tumor proliferation, invasion, metabolic switch, angiogenesis,
immune surveillance and therapy resistance, which all contribute
to poor patient survival, the article discusses CAF-targeting
therapies. The potential strategies discussed in the article include
inhibiting CAF activation or function (e.g., inhibiting TGF-β or
CXCL12/CXCR4 signaling pathways), “normalizing” CAF (e.g.,
NOX4 inhibitors) or killing CAF (e.g., FAP-based depletion).
Although these strategies are promising, caution is required
because those molecules are widely expressed in different
conditions and tissues and their targeting may result in many
side effects.
The participation of the sympathetic nervous system in
the development and progression of HNSCC was explored in
Vincent-Chong and Seshadri, by investigating the neurovascular
interactions mediated via the adrenergic signaling. This study
also brought a basis to support the therapeutic potential for
HNSCC of directly targeting adrenergic signaling in tumor cells
or indirectly targeting neurovascular interactions.
This Research Topic is a useful reference of the current
understanding about the vital role of TME in oral cancer
development and progression, highlighting its potential to
development of new strategies for oral cancer treatment.
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